SOPHiA GENETICS Q3 EPS Estimate Lowered by HC Wainwright

Key Points

• HC Wainwright lowered SOPHiA GENETICS’ Q3 2026 EPS estimate to a loss of $0.13 per share from $0.12, while maintaining a Buy rating and $14 price target.
• SOPHiA GENETICS reported a quarterly loss of $0.26 per share, missing the $0.21 consensus estimate, although revenue of $23.31 million exceeded expectations of $21.72 million.
• Analyst sentiment is mixed: three analysts rate the stock Buy, one rates it Hold and one rates it Sell, producing a consensus Hold rating and $10 average price target. Shares opened at $6.69, near their 12-month high of $7.21.

SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2026 EPS estimates for SOPHiA GENETICS in a report issued on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.12). HC Wainwright has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for SOPHiA GENETICS's current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS's Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.77) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.02) EPS.

Several other research firms have also recently commented on SOPH. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $6.69 on Friday. The business's 50-day moving average price is $5.57 and its 200 day moving average price is $5.13. SOPHiA GENETICS has a twelve month low of $2.96 and a twelve month high of $7.21. The company has a market capitalization of $561.22 million, a PE ratio of -5.82 and a beta of 0.96. The company has a current ratio of 2.69, a quick ratio of 1.90 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the completion of the sale, the chief executive officer owned 3,601,493 shares of the company's stock, valued at $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 10,000 shares of the firm's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00. Following the completion of the transaction, the insider directly owned 600,887 shares in the company, valued at approximately $4,158,138.04. This represents a 1.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 256,092 shares of company stock valued at $1,492,420 over the last ninety days. Corporate insiders own 4.88% of the company's stock.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. purchased a new position in SOPHiA GENETICS in the second quarter valued at about $567,000. Royal Bank of Canada boosted its position in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after buying an additional 18,781 shares during the period. Sei Investments Co. purchased a new stake in shares of SOPHiA GENETICS in the first quarter worth about $1,772,000. Principal Financial Group Inc. grew its stake in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after buying an additional 9,800 shares in the last quarter. Finally, Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $2,157,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, implying 22%–24% year-over-year growth and exceeding the roughly $93.4 million consensus estimate. Management continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook article
• Positive Sentiment: The company entered a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The partnership could expand SOPH’s commercial reach and provide longer-term growth opportunities. SOPHiA GENETICS AstraZeneca partnership article
• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target from $12 to $14. BTIG Research also maintained a Buy rating and lifted its target from $8 to $9, signaling improved confidence in the company’s growth prospects.
• Positive Sentiment: Second-quarter revenue rose 27% year over year to $23.31 million, surpassing the $21.72 million consensus estimate. The adjusted EBITDA loss also improved by 27% to $8.8 million.
• Neutral Sentiment: HC Wainwright reduced its FY2029 EPS estimate to $0.31 from $0.34 but increased its FY2030 forecast to $0.72 from $0.69. The firm’s $14 target and Buy rating were unchanged, suggesting near-term forecast pressure but stronger longer-term expectations.
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu sold a combined 35,000 shares for approximately $242,350 under pre-arranged Rule 10b5-1 plans. Their remaining ownership stakes declined only modestly, reducing the significance of the sales as a bearish signal.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the expected $0.21 loss. The company remains deeply unprofitable, with a negative net margin and analysts forecasting a full-year loss of approximately $0.58 per share.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source